Yesterday, Uri Yaron, Senior Vice President of Abbott, announced on LinkedIn that its self-developed TactiFlex Duo sensor catheter had officially received the "Breakthrough Device" designation from the U.S. FDA, marking a key advancement for Abbott in the highly competitive pulsed field ablation market.

The product innovatively adoptsDual-energy ModeDesign, through the synergistic effect of pulsed field ablation (PFA) and radiofrequency ablation (RF), to provide precise targeted therapy for patients with ventricular tachycardia (VT).

Abbott TactiFlex Duo Sensor Enabled Ablation System

According to Yaron, the FDA Breakthrough Therapy Designation requires meeting two core criteria: the product must address an unmet clinical need and demonstrate the potential to offer a superior treatment option for life-threatening diseases.The TactiFlex Duo catheter is a prime example of this standard — its unique flexible tip design supports "focused" point-by-point ablation, which can disrupt abnormal electrical signal pathways with high-precision pulsed electric fields and also switch to radiofrequency energy for traditional ablation. The dual mechanism significantly reduces the risk of damage to adjacent tissues, making it particularly suitable for patients with complex cardiac anatomical structures.

Market dynamics show that Abbott is accelerating its layout in the PFA field.In March 2025, its Volt PFA System received EU CE certification, with plans to expand coverage in the European market by the end of the year. The approval of TactiFlex Duo will create a technological synergy with the Volt system, establishing a comprehensive ablation solution matrix for multiple conditions such as atrial fibrillation and ventricular tachycardia.

From the perspective of industry competition, the competition in the PFA field has reached a fever pitch.

Boston ScientificIts Farapulse system, with a first-mover advantage, achieved global sales of over $1 billion (approximately 7.2 billion yuan) in 2024, becoming the fastest-growing single product.This product originated from Boston Scientific's $500,000 seed investment in the startup Farapulse in 2013. After the merger and integration in 2021, it received FDA approval in January 2024 and has now benefited more than 200,000 patients in Europe, the U.S., China, and Japan, reshaping the market landscape for atrial fibrillation ablation.MedtronicFang Ye also took up the challenge without hesitation,LatestThe financial report shows that the growth rate of its PFA products in the U.S. market reached 72%.Johnson & JohnsonMedical technology continues to invest heavily in this field.

Two years ago,Stifel's analysts have expressed concerns, stating that under the first-mover advantage of Medtronic, Johnson & Johnson, and Boston Scientific in the PFA field, Abbott's $1.9 billion (approximately RMB...13.6 billion yuan) is under tremendous threat in terms of electrophysiology business.

At present, facing fierce competition from industry giants, Abbott is breaking through with technological innovation. The breakthrough certification of TactiFlex Duo also confirms Abbott's efforts in the PFA market. Perhaps in the near future, the PFA field will witness a new competitive landscape.